United Therapeutics Corporation vs Soleno Therapeutics, Inc.: Strategic Focus on R&D Spending

R&D Spending: United Therapeutics vs. Soleno Therapeutics

__timestampSoleno Therapeutics, Inc.United Therapeutics Corporation
Wednesday, January 1, 20142242216242549000
Thursday, January 1, 20154536244245098000
Friday, January 1, 20165184803147600000
Sunday, January 1, 20173068742264600000
Monday, January 1, 20187178000357900000
Tuesday, January 1, 2019162670001182600000
Wednesday, January 1, 202023191000357700000
Friday, January 1, 202121453000540100000
Saturday, January 1, 202215265000322900000
Sunday, January 1, 202325189000408000000
Loading chart...

Unlocking the unknown

Strategic Focus on R&D Spending: A Tale of Two Companies

In the competitive landscape of biotechnology, research and development (R&D) spending is a critical indicator of a company's commitment to innovation. Over the past decade, United Therapeutics Corporation and Soleno Therapeutics, Inc. have demonstrated contrasting strategies in their R&D investments. From 2014 to 2023, United Therapeutics consistently allocated substantial resources, with an average annual R&D expenditure of approximately $407 million, peaking at $1.18 billion in 2019. This reflects a robust commitment to advancing their pipeline and maintaining a competitive edge.

Conversely, Soleno Therapeutics, with a more modest average annual R&D spend of around $12 million, saw a significant increase in 2023, reaching $25 million. This surge suggests a strategic pivot towards enhancing their research capabilities. The disparity in R&D spending between these two companies highlights differing approaches to growth and innovation in the biotech sector.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025